Sio Gene Therapies to Present at the UBS Global Healthcare Virtual Conference
05/19/2021 - 08:00 AM
NEW YORK and RESEARCH TRIANGLE PARK, N.C, May 19, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will present and participate in 1-on-1 investor meetings at the UBS Global Healthcare Virtual Conference taking place May 24-26, 2021.
Details on the presentation can be found below.
Date: Monday, May 24, 2021 Time: 10:00 AM ET Participation Format: Company presentation Presenter: Pavan Cheruvu, MD, Chief Executive Officer Webcast: Click here
About Sio Gene Therapies
Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Our current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies. We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinson’s disease, which affects millions of patients globally. Led by an experienced team of gene therapy development experts, and supported by collaborations with premier academic, industry and patient advocacy organizations, Sio is focused on accelerating its candidates through clinical trials to liberate patients with debilitating diseases through the transformational power of gene therapies. For more information, visit www.siogtx.com .
Contacts:
Media
Josephine Belluardo, Ph.D.jo@lifescicomms.com info@siogtx.com
Investors and Analysts
Parag V. Meswani, PharmDinvestors@siogtx.com
SIOX Rankings
N/A Ranked by Stock Gains
SIOX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
United Kingdom
City
11 12 St Jamess Square
About SIOX
axovant develops transformative gene therapies for patients with life-altering neurologic conditions. our mission is to identify, develop, and bring to market high-impact therapies that have the potential to improve the lives of patients with neurological disorders. our team is made up of leading scientific experts who are passionate about treating neurological conditions and easing the burden of these life-changing disorders for both patients and caregivers. our team is motivated by the promise of novel drug development, and is driven to find more efficient and effective ways to conduct scientific and clinical evaluations that rapidly deliver impactful medicines to patients in need. our leadership team has a track record bringing innovative new neurotherapeutic treatments to a global market, and along with our seasoned board of directors, is fully committed to the responsible pursuit of transformative therapies for some of the world's most difficult conditions.
